# The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-association-of-acquired-t790m-mutation-with-clinical-characteristics-after/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yen-Hsiang Huang,Kuo-Hsuan Hsu,Jeng‐Sen Tseng,Kun‐Chieh Chen,Chia-Hung Hsu,Kang‐Yi Su,Jeremy J.W. Chen,Huei‐Wen Chen,Sung‐Liang Yu,Tsung‐Ying Yang,Gee‐Chen Chang |
| Citations | 63 |
| DOI | 10.4143/crt.2017.512 |
| Fields | Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | http://www.e-crt.org/upload/pdf/crt-2017-512.pdf |
| OpenAlex ID | https://openalex.org/W2781648434 |
| PMID | 29334606 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Jeng‐Sen Tseng](https://scholariq.org/researchers/jeng-sen-tseng/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.